Exercise prescription dose for castrate-resistant prostate cancer patients: a phase I prescription dose escalation trial.

Renée BultijnckBenedicte DeforcheNoëmi BorreyJörgen Van BauwelMaarten LievensElke RammantValérie FonteyneKarel DecaesteckerAdelheid SteyaertNicolaas LumenPiet Ost

Published in: World journal of urology (2020)

Our findings suggest that exercise is perceived tolerable in mCRPC patients receiving second-line hormone therapy. Caution is indicated on safety during performance of the exercises.

Keyphrases

physical activity
high intensity
resistance training
prostate cancer
clinical trial
social support
study protocol
mental health
open label
phase ii
phase iii
body composition
benign prostatic hyperplasia
stem cells
cell therapy